Impact News +++ Microbot Shares Rise on FDA Clearance for LIBERTY Robotic System (Zacks) +++ MICROBOT Aktie +4,25%

ROYALTY PHARMA Aktie

>ROYALTY PHARMA Aktienkurs

30.66 EUR +0.7% (Tradegate)

Ask: 31.24 EUR / 110 Stück

Bid: 31.12 EUR / 110 Stück

Tagesumsatz: 137 Stück

Realtime Kurs von 7:30 bis 22 Uhr!

Aktie über LYNX handeln

Intraday

1 Jahr

>ROYALTY PHARMA Performance

1 Woche: -1,7%

1 Monat: -5,1%

3 Monate: +4,1%

6 Monate: -0,5%

1 Jahr: +20,8%

laufendes Jahr: +25,8%

>ROYALTY PHARMA Aktie

Name:

ROYALTY PHARMA OA DL-0001

Land:

Großbritannien

Sektor:

Gesundheit

ISIN/ Wkn:

GB00BMVP7Y09 / A2P62D

Symbol/ Ticker:

RPD (Frankfurt) / RPRX (NASDAQ)

Kürzel:

FRA:RPD, ETR:RPD, RPD:GR, NASDAQ:RPRX

Index:

Webseite:

https://www.royaltypharma..

Profil:

Royalty Pharma plc is a unique player in the pharm..
>Volltext..

Marktkapitalisierung:

17756.5 Mio. EUR

Unternehmenswert:

26696.51 Mio. EUR

Umsatz:

1960.75 Mio. EUR

EBITDA:

1564.84 Mio. EUR

Nettogewinn:

867.87 Mio. EUR

Gewinn je Aktie:

1.96 EUR

Schulden:

6820.62 Mio. EUR

Liquide Mittel:

537.39 Mio. EUR

Operativer Cashflow:

2143.24 Mio. EUR

Bargeldquote:

0.53

Umsatzwachstum:

-6.31%

Gewinnwachstum:

37.7%

Dividende je Aktie:

0.78 EUR

Dividendenrendite:

2.41%

Dividendenschätzung:

2.46%

Div. Historie:

15.08.25 - 0.187902€
16.05.25 - 0.197384€

>weitere anzeigen...

Insiderhandel:

1 Insider verkaufte innerhalb der letzten 30 Tage Aktien im Wert von 1.213.749 USD.

Suchwörter:

ROYALTY PHARMA

Letzte Datenerhebung:

09.09.25

>Kennzahlen

Aktien/ Unternehmen:

Aktien: 432.29 Mio. St.

Frei handelbar: 78.81%

Leerverk. Aktien: 3.25%

Rückkaufquote: 5.51%

Mitarbeiter: 99

Umsatz/Mitarb.: 19.44 Mio. EUR

Analysten:

Analystenrating: Buy

Kursziel: 26.45%

Bewertung:

KGV: 15.48

KGV lG: 7.92

KUV: 8.73

KBV: 2.42

PEG-Ratio: 0.29

EV/EBITDA: 17.06

Rentabilität:

Bruttomarge: -

Gewinnmarge: 44.26%

Operative Marge: 79.81%

Managementeffizenz:

Gesamtkaprendite: 5.67%

Eigenkaprendite: 15.92%

>Peer Group

Es sind 81 Aktien bekannt.

>ROYALTY PHARMA Chart & Kurs - NASDAQ

>ROYALTY PHARMA News

04.09.25 - 22:18	Royalty Pharma to Present at the Morgan Stanley 23rd Annual Global Healthcare Conference (GlobeNewswire EN)
	NEW YORK, Sept. 04, 2025 (GLOBE NEWSWIRE) -- Royalty Pharma plc (Nasdaq: RPRX) today announced that it will participate in a fireside chat at the Morgan Stanley 23rd Annual Global Healthcare Conference on Tuesday, September 9, 2025 at 3:20 p.m. ET....

03.09.25 - 07:30	Royalty Pharma prices $2B senior unsecured notes (SeekingAlpha)
	Um den gesamten Artikel unter seekingalpha.com zu lesen, klicken Sie bitte auf die Überschrift...

03.09.25 - 03:54	Royalty Pharma Prices $2 Bln Offering Of Senior Unsecured Notes (AFX)
	WASHINGTON (dpa-AFX) - Royalty Pharma plc (RPRX) announced the pricing of a $2.0 billion offering of senior unsecured notes. The issuance includes $600 million of 4.450% Notes due 2031, $900 milli......

03.09.25 - 02:33	Royalty Pharma Announces Pricing of $2.0 Billion of Senior Unsecured Notes (GlobeNewswire EN)
	NEW YORK, Sept. 02, 2025 (GLOBE NEWSWIRE) -- Royalty Pharma plc (Nasdaq: RPRX) announced today that it has priced an offering of $2.0 billion of senior unsecured notes, comprised of the following (collectively, the “Notes”):...

02.09.25 - 14:54	Zenas BioPharma Secures Up To $300 Mln Funding From Royalty Pharma For Obexelimab (AFX)
	WASHINGTON (dpa-AFX) - Royalty Pharma plc (RPRX) and Zenas BioPharma, Inc. (ZBIO) Tuesday announced that Royalty Pharma will provide up to $300 million in exchange for a royalty on sales of obexel......

02.09.25 - 14:24	Zenas BioPharma and Royalty Pharma enter into Obexelimab funding agreement for $300M (SeekingAlpha)
	Um den gesamten Artikel unter seekingalpha.com zu lesen, klicken Sie bitte auf die Überschrift...

02.09.25 - 13:18	Royalty Pharma and Zenas BioPharma Enter Into Obexelimab Funding Agreement for Up to $300 Million (GlobeNewswire EN)
	NEW YORK and WALTHAM, Mass., Sept. 02, 2025 (GLOBE NEWSWIRE) -- Royalty Pharma plc (Nasdaq: RPRX) and Zenas BioPharma, Inc. (Nasdaq: ZBIO) today announced that Royalty Pharma will provide up to $300 million in funding in exchange for a royalty on sales of obexelimab....

02.09.25 - 13:09	Zenas BioPharma and Royalty Pharma Enter into Obexelimab Funding Agreement for up to $300 Million (GlobeNewswire EN)
	- Initial $75 million to fund the potential U.S. commercial launch of obexelimab for the treatment of IgG4-Related Disease -...

25.08.25 - 12:54	Royalty Pharma Acquires Royalty Interest In Imdelltra From BeOne (AFX)
	WASHINGTON (dpa-AFX) - Royalty Pharma plc (RPRX) has acquired a royalty interest in Amgen's Imdelltra, a DLL3 targeting bispecific T-cell engager, from BeOne Medicines for $885 million upfront. Th......

25.08.25 - 12:39	Royalty Pharma to buy royalty interest in Amgen′s lung cancer drug for up to $950 million (Reuters EN)
	Um den gesamten Artikel unter investing.com zu lesen, klicken Sie bitte auf die Überschrift...

25.08.25 - 12:21	Royalty Pharma to buy royalty interest in Amgen’s Imdelltra for up to $950M (SeekingAlpha)
	Um den gesamten Artikel unter seekingalpha.com zu lesen, klicken Sie bitte auf die Überschrift...

25.08.25 - 12:12

Royalty Pharma to Acquire Royalty Interest in Amgen′s Imdelltra for up to $950 Million (GlobeNewswire EN)

NEW YORK, Aug. 25, 2025 (GLOBE NEWSWIRE) -- Royalty Pharma plc (Nasdaq: RPRX) today announced that it has acquired a royalty interest in Amgen's Imdelltra, a first-in-class DLL3 targeting bispecific T-cell engager (BiTE), from BeOne Medicines for $885 million upfront. The agreement includes an option for BeOne to sell additional Imdelltra royalties to Royalty Pharma for up to $65 million within the next 12 months....

14.08.25 - 23:42	XFRA: DIVIDEND/INTEREST INFORMATION - 15.08.2025 - GB00BMVP7Y09 (XETRA)
	Das Instrument RPD GB00BMVP7Y09 ROYALTY PHARMA OA DL-0001 EQUITY wird ex Dividende/Zinsen gehandelt am 15.08.2025 The instrument RPD GB00BMVP7Y09 ROYALTY PHARMA OA DL-0001 EQUITY has its ex-dividend/interest day on 15.08.2025...

13.08.25 - 22:18	Henry Fernandez Steps Down from Royalty Pharma′s Board of Directors (GlobeNewswire EN)
	NEW YORK, Aug. 13, 2025 (GLOBE NEWSWIRE) -- Royalty Pharma plc (Nasdaq: RPRX) today announced that Henry Fernandez, its Lead Independent Director, has stepped down from its Board of Directors, effective August 13, 2025. Mr. Fernandez joined the Royalty Pharma Board of Directors in July 2020 and was unanimously appointed as Lead Independent Director in March 2021....

12.08.25 - 04:01	Insiderhandel: Aufsichtsrat verkauft Aktien von Royalty Pharma Plc im Wert von 1213749 USD (Insiderkauf)
	Norden, Gregory - Aufsichtsrat - Tag der Transaktion: 2025-08-11...

07.08.25 - 03:12	Royalty Pharma (RPRX) Q2 Receipts Up 20% (Fool)
	Um den gesamten Artikel unter fool.com zu lesen, klicken Sie bitte auf die Überschrift...

07.08.25 - 02:42	Royalty Pharma Plc Q2 Income Retreats (AFX)
	WASHINGTON (dpa-AFX) - Royalty Pharma plc (RPRX) released a profit for second quarter that Drops, from the same period last yearThe company's earnings came in at $30.17 million, or $0.07 per share......

06.08.25 - 21:57	Royalty Pharma raises 2025 portfolio receipts guidance to $3.05B-$3.15B as integrated company advances biotech funding model (SeekingAlpha)
	Um den gesamten Artikel unter seekingalpha.com zu lesen, klicken Sie bitte auf die Überschrift...

06.08.25 - 16:30	Here′s What Key Metrics Tell Us About Royalty Pharma (RPRX) Q2 Earnings (Zacks)
	The headline numbers for Royalty Pharma (RPRX) give insight into how the company performed in the quarter ended June 2025, but it may be worthwhile to compare some of its key metrics to Wall Street estimates and the year-ago actuals....

06.08.25 - 16:00	Royalty Pharma (RPRX) Tops Q2 Earnings and Revenue Estimates (Zacks)
	Royalty Pharma (RPRX) delivered earnings and revenue surprises of +3.64% and +5.94%, respectively, for the quarter ended June 2025. Do the numbers hold clues to what lies ahead for the stock?...

>weitere News anzeigen...

>Impressum >Über uns >Datenschutz >Financial Data & Solutions

>Behalte deine Investments mit realtime Kursen & News im Blick. Finde neue spannende Aktien! Registriere Dich und werde Mitglied!

Zitat des Tages: Weit besser ist′s, sie einzuengen, daß man sie wie Kinder halten, wie Kinder zu ihrem Besten leiten kann. Glaube nur, ein Volk wird nicht alt, nicht klug, ein Volk bleibt immer kindisch. - Johann Wolfgang von Goethe

Partner: >Tradegate Börse | >Dukascopy | >Boersentreff- Partner

Börsentreff auf Facebook |

Börsentreff auf X |

Börsentreff auf Instagram